康方生物、沛嘉医疗等6家带"B"字标识的生物科技公司进入港股通
康方生物-B、沛嘉医疗-B、诺诚健华-B、康宁杰瑞制药-B、亚盛医药-B、启明医疗-B等6家带"B"字标识的生物科技公司今日起正式纳入港股通股票范围。
12月25日,上交所发布公告,根据《上海证券交易所沪港通业务实施办法》有关规定及沪深港3所达成的共识,对符合沪港通下港股通(以下简称港股通)纳入条件,按照香港联合交易所《主板上市规则》第18A章节上市,且股份名称结尾有“B”字标识的生物科技公司股票实施首次纳入调整,并自下一港股通交易日起生效。相关调整信息如下:

12月25日,深交所发布公告,根据《深圳证券交易所深港通业务实施办法》的有关规定及深沪港交易所达成的共识,按照香港联合交易所《主板上市规则》第18A章节上市的,股份名称结尾有“B”字标识的生物科技公司的股票自2020年12月28日起纳入港股通股票范围,相关调整信息如下:

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.